Exparel for Nerve Blocks

[sevoflurane]

---

Members don't see this ad.

Incidentally, some fun reading through those old stock picking threads.

I'm more convinced than ever that one shouldn't get their stock picking advice off a board full of doctors ... 🙂

Some of the more concrete predictions:


On March 10, 2013:

He was right ... hit $50 in Oct 2013. Peaked at$117 in February 2015.

On August 16, 2014:

Pacira was about $100 then. Now it's at $45.

On October 30, 2014:

Pacira was at $92 that day.

On April 30, 2015:

Pacira had just dipped below $70 in April 2015, after its peak of $117 two months earlier. Where was it by Q4 2015? Well, in October it was $37. before briefly flirting with the $70s in December.

$45 today.

Hey we're is my post where I sold and never bought back in?

😡🙂

Exparel is dead in the water.

 

[pgg]

I am a podiatrist. I have used exparel and have decided bupivacaine is better for foot blocks. It all started when I blocked a bunion patient who had pain on post op day 2. I promised at least a full 24 hours of relief (I forget why he opted for this over oral narcotics ). He said the exparel effect was minimal. So I did a block on my own foot, and wasn't impressed with the effect, early or late. The block wasn't really solid, and yes I have done many of the fundamental local blocks on my own feet, kinda weird I know.

Hardcore.

Not Karl "cocaine in my own eyeball" Koller hardcore, but hardcore. 🙂

 

[BLADEMDA]

Hey we're is my post where I sold and never bought back in?

😡🙂

Exparel is dead in the water.

Down but not out. I do agree that PCRX has a long road ahead towards profitability in order to justify its stock price. That said, I like the drug and could see Big Pharma buying them out if PCRX stock continues its decline.

 

[BLADEMDA]

 

[BLADEMDA]

 

[pgg]

 

[BLADEMDA]

FYI, I purchase ETFs these days and rarely ever buy an individual stock. The last stock I purchased was Gilead and it was a small purchase. Instead, I utilize ETFs to play the "long game" and buy undervalued sectors (small part of my portfolio). Doze has convinced me that individual stock risk isn't worth it at this point in my career.

 

[epidural man]

I

Pacira was about $100 then. Now it's at $45.

On October 30, 2014:

Pacira was at $92 that day.

.

Not true. You only need an IND if you think the new route of administration significantly increases the risk of the drug and it's an individual IRB issue, not an FDA issue. Also, while it's true a retrospective analysis doesn't "answer the question", it begs the question why there hasn't been one published that suggests the answer. Because the data is out there and Pacira would pay people to publish it if it helped their cause.

I guess we will have to disagree on this point - unless you can give an example of where the FDA gave an IND waiver - or told the applicant an IND wasn't needed - otherwise, based on my own experience with the FDA, I think I'm right about this (but happy to be wrong).